FZFabien ZoulimMD, PhDSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Is there a best Direct Acting Antiviral in development?- Fabien Zoulim, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Is there a best immunomodulator in development?- Ulrike ProtzerView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Is There a Best Host Acting Antiviral for HBV Cure?- Jake LiangView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017HEV Update: Diagnostics and Management- Kenneth Sherman, MD, PhDView Slideset
FZFabien ZoulimMD, PhDSlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Revisiting the Molecular and Cell Biology of the Hepatitis B Virus Towards Elimination- Fabien Zoulim, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Emerging Therapeutic Targets and Concepts for Delta Hepatitis Virus (not yet available) - Jeffrey GlennView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017A novel immunotherapy for chronic HBV and HDV infections that bypass tolerance and induce broadly crossreactive and neutralizing antibodies (not available)- Dr. M. SallbergView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Development of Immune Competent Small Animal Models for HBV- Helene Strick-MarchandView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017In vivo evaluation of anti-HBV CRISPR/Cas9 therapy in the FRG mouse- Dr. K. JeromeView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Targeting the HBV-Macrophage-Stellate cell axis to treat HBV-induced Liver Diseases- Lishan SuView Slideset
SlidesetViral Hepatitis and Liver DiseaseHEP DART 2017Core Antibody: anti-HBc What is the Core of the Story?- Robert Gish, MDView Slideset
